Chief Scientific Officer
Andrew Catchpole first studied as a virologist at the University of Warwick before then furthering his education with postgraduate studies in influenza replication at Oxford University. Since then he has applied his scientific knowledge in a commercial setting. After working as part of a multidisciplinary R&D team developing nuclear medicine research tools at GE Healthcare, he then returned to the field of virology to work for hVIVO and Open Orphan, an industry-leading service provider of human viral challenge studies (controlled human infection studies). Andrew is now considered an expert in human viral challenge studies having played key roles in the development of influenza, RSV and HRV models at hVIVO. He has overseen the design and conduct of numerous antiviral and vaccine product efficacy studies and now works as Chief Scientist in the company providing both internal consultancy as well as advising hVIVO’s clients and collaborators on challenge study design. In addition, he was PI on a recent successfully completed DARPA-sponsored research project to utilise the challenge model to identity human biomarkers and algorithms prognostic of influenza contagiousness.